Navigation Links
CSL Behring's Helixate(R) FS Now Available in 2000 IU Vial Size to Improve Patient Convenience, Encourage Compliance
Date:12/21/2007

KING OF PRUSSIA, Pa., Dec. 21 /PRNewswire/ -- CSL Behring today announced that Helixate(R) FS, its advanced recombinant FVIII (rFVIII) product for the treatment of hemophilia A, is now available in the United States in a new 2000 IU (international unit) vial size. For patients requiring high doses of Helixate FS, the 2000 IU vial size reduces reconstitution time by eliminating the need to mix and pool multiple vials.

"Helixate FS, with the new 2000 IU vial, offers patients shorter infusion times, which translates into greater convenience, and will encourage compliance with prescribed treatment," said Robert Lefebvre, vice president and general manager, U.S. Commercial Operations. "The introduction of the 2000 IU vial is a solid example of CSL Behring's ongoing commitment to advancing hemophilia therapy management and improving convenience for patients."

Use of Helixate FS in conjunction with CSL Behring's new HeliTrax(SM) system can improve patient-physician communication and therapy management. The HeliTrax system combines an Internet-based encrypted database for professionals to track treatment and a wireless hand-held electronic diary for patients to log infusions and treatments with recombinant FVIII Helixate FS.

"Combining Helixate FS with HeliTrax may be ideal for the active, growing teen with hemophilia A who needs more factor product," said Jill Leone, RN, CCRP, nurse consultant. "Enhancing the system with the 2000 unit vial dosage will further improve convenience and communication, and enable teens to begin to manage the disease independently."

Helixate FS is packaged with the Mix2Vial, an easy-to-use, plastic, needle-free transfer device with a built-in filter. Use of the Mix2Vial helps minimize the risk of injury and reduces product preparation time.

For more information about Helixate FS and the 2000 IU vial, please visit http://www.cslbehring.com or call CSL Behring Consumer Affairs at 1-888-508-6978.

About Helixate(R) FS

Helixate(R) FS is a recombinant factor VIII treatment for hemophilia A that offers convenient administration with a 2.5-mL volume diluent; no available factor VIII product has a smaller diluent size. The new 2000 vial size requires a 5.0 mL volume diluent.

No albumin is used in the formulation or purification of Helixate FS, and its manufacture includes a solvent/detergent viral inactivation step. The most frequently reported adverse event is local injection-site reaction. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Helixate FS. In 2006, the FDA gave approval for Helixate FS to be stored at room temperature (up to 25 degrees C, 77 degrees F) for three months. The new storage guidelines for the treatment provide users with greater flexibility and simplify storage options

Helixate(R) FS is manufactured by Bayer HealthCare LLC for CSL Behring LLC.

About Hemophilia

Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. About 17,000 Americans have hemophilia. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX.

About CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit http://www.cslbehring.com.

Media Contact:

Sheila A. Burke

Director, Public Relations & Communications

Worldwide Commercial Operations

CSL Behring

610-878-4209

Sheila.Burke@cslbehring.com


'/>"/>
SOURCE CSL Behring
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
2. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
3. Tickets Still Available for Detroit Uncorked;
4. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
5. Experts, Advocates Available to Comment on Hillary Clintons Health Care Plan
6. Fingertip Formulary Mobile(TM) is Now Available for Physicians and Other Healthcare Providers Free on PDAs
7. New Resource for Taking Care of Aging Parents Available in Beta
8. 2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available
9. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
10. Updated Brochure on Gynecologic Cancer Treatments Now Available
11. Help is Available for Smokers Who Want to Quit as Minnesotas Smoke-Free Law Takes Effect Oct. 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... IL (PRWEB) , ... May 24, 2017 , ... ... the most prominent for-profit and nonprofit hospitals and health systems in the nation ... turned around their institutions, led professional organizations and been instrumental in developing successful ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... Population Health and Clinical Integration company, announced today that its iClinic V12.2 solution ... (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize team-based ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... have remained steady since 2009, according to a Workers Compensation Research Institute (WCRI) ... Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition looks at ...
(Date:5/23/2017)... ... , ... London, May 23, 2017: Walter Schindler, the Founder and Managing Partner ... Speaker and Contributor to a weeklong series of classes, meetings, field trips and special ... Walter Schindler and SAIL Capital have received an increasing number of ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech For Solutions has announced ... laboratory, to provide hands-on training utilizing cutting-edge equipment at its recently-opened OvaTools Andrology ... MedTech Group Purchasing vendor , will provide specialized equipment to ensure OvaTools participants ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... Mass., May 10, 2017 Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended April 1, ... of $1.84 increased 666.7% compared to the prior year ... resulted in a significant gain, while non-GAAP diluted EPS ... 3.2%, or 3.8% in constant currency terms.  Excluding the ...
(Date:5/10/2017)... Radiology has become the number one diagnostic ... spiraled to the number one ranking as a result.  ... before as the most complete and reliable method for ... back pain an MRI may confirm a suspected herniated ... in entirely different treatment protocols.  In these circumstances, patients ...
(Date:5/9/2017)...  Demonstrating its commitment to representing research- based ... Pharmaceutical Research and Manufacturers of America (PhRMA) today ... now have to meet new research and development ... join PhRMA. "By putting in place ... clear message that being a member of PhRMA ...
Breaking Medicine Technology: